$IRMD

Scharen-Guivel Hilda Frederique sold $168K of IRMD

Scharen-Guivel Hilda Frederique sold 1,766 shares of IRADIMED CORP (IRMD) at $95.00 ($0.17M total) on 2026-06-04.

Original reporting
SEC EDGAR · Scharen-Guivel Hilda Frederique
Published Jun 4, 2026, 8:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRMD
Neutral
medium confidence
Mentioned
$IRMD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRMDNeutralLow
01

Why it matters

The disclosure may influence trader sentiment around IRMD but does not change the company’s fundamentals by itself.

02

Market read

Use as a sentiment/positioning input rather than a standalone catalyst.

03

What to watch

Sale size is small relative to typical company float; without follow-on filings or pattern, signal-to-noise is limited.

Relevance 6/10Novelty 8/10Timing: today’s SEC Form 4 disclosure (2026-06-04)

Background

The article reports an SEC Form 4 insider transaction by a director of IRADIMED CORP (IRMD).

Company-level read

Ticker impact

$IRMDNeutralMedium confidence
Context

Director sold 1,766 shares in an open-market transaction on 2026-06-04 at $95.00/share, disclosed via SEC Form 4.

Expected impact

Low-to-moderate short-term negative bias; likely limited follow-through absent other catalysts.

Evidence & confidence

The filing is a disclosed ownership change (not a corporate action) and provides no new operating/financial information; impact depends on whether the sale is interpreted as non-routine.

Market effects

No clear sector read-through from a single director sale without additional company/industry news.

None indicated.

None indicated.

Counterpoint

A non-10b5-1 sale can reflect diversification, taxes, or liquidity needs rather than bearish fundamentals.

Key entities

  • IRADIMED CORP

    Subject of the SEC Form 4 insider sale disclosure.

  • Scharen-Guivel Hilda Frederique

    Director who sold 1,766 shares on 2026-06-04.

Related articles

$IRMDMedAI 9/10

IRadimed (IRMD) Q2 2026 Earnings Call Transcript

IRadimed (IRMD) reported Q2 2026 revenue of $20.5 million, up 0.5% from $20.4 million a year earlier. GAAP diluted EPS was $0.41 versus $0.45, and non-GAAP EPS was $0.46. Gross margin fell to 74% from 78% due to higher manufacturing costs during the 3870 pump ramp. Q3 revenue guidance is $23.0 to $24.5 million; full-year 2026 revenue guidance is $91 to $96 million.

$IRMDMedAI 9/10

Iradimed Corp (IRMD): 3 Things That Stood Out From Q1 Report

Iradimed Corp (IRMD) reported Q1 2026 results on May 1. The company said revenue rose 13% year over year to $22 million and net income increased 24% to $5.8 million, or $0.45 per share. Iradimed also launched its next-generation 3870 MRI-compatible IV infusion pump in Q1, with shipments expected to begin in Q2. For Q2, it forecast revenue of $20–$21 million and GAAP EPS of $0.40–$0.44; full-year 2026 revenue of $91–$96 million and GAAP EPS of $1.90–$2.05.